Get the Stockscreener App
15.58
6.54%
-1.09
After Hours:
15.58
Tandem Diabetes Care Inc stock is traded at $15.58, with a volume of 1.81M.
It is down -6.54% in the last 24 hours and down -16.42% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$16.67
Open:
$16.3
24h Volume:
1.81M
Relative Volume:
1.12
Market Cap:
$1.04B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-7.4545
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
+0.91%
1M Performance:
-16.42%
6M Performance:
-57.96%
1Y Performance:
-57.87%
1-Day Range:
$15.52
$16.30
1-Week Range:
$15.21
$17.19
52-Week Range:
$14.31
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.58 | 1.11B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care Announces Upcoming Conference Participation - Business Wire
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Tandem Diabetes Care (NASDAQ:TNDM) Shareholders Are up 15% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
Tandem Diabetes Care Inc.’s Price Action Aligns with Quant SignalsReliable Investment Entry Signals Confirmed by Charts - metal.it
Wyckoff Accumulation Phase Possible in Tandem Diabetes Care Inc.AI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 04:06:14 - metal.it
Quant Strategy Flags Tandem Diabetes Care Inc. for EntryConsistent Profit Pattern Recognition Tools Shared - metal.it
Tandem Diabetes Care Stock Rebounds as Investors Eye Earnings ReportNews and Statistics - IndexBox
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today - TradingView
What are analysts’ price targets for Tandem Diabetes Care Inc. in the next 12 monthsMassive portfolio appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Tandem Diabetes Care Inc. stockBuild a portfolio that stands the test of time - jammulinksnews.com
Is it the right time to buy Tandem Diabetes Care Inc. stockDiscover hidden gems in the stock market - jammulinksnews.com
How does Tandem Diabetes Care Inc. compare to its industry peersAdvanced Screener Ideas For Fast Growth - jammulinksnews.com
What institutional investors are buying Tandem Diabetes Care Inc. stockSuperior risk-adjusted returns - jammulinksnews.com
How strong is Tandem Diabetes Care Inc. company’s balance sheetCapitalize on fast-growing stocks today - jammulinksnews.com
Tandem Diabetes Care Inc. Stock Support and Resistance Levels You Should KnowPotential Rocket List - metal.it
What is Tandem Diabetes Care Inc. company’s growth strategyStrong return on assets - jammulinksnews.com
What are the latest earnings results for Tandem Diabetes Care Inc.Invest smarter with daily trading signals - jammulinksnews.com
What are Tandem Diabetes Care Inc. company’s key revenue driversInvest smarter with real-time trading signals - jammulinksnews.com
Why Tandem Diabetes Care Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - metal.it
What makes Tandem Diabetes Care Inc. stock price move sharplyFree Stock Market Insider Analysis - metal.it
What analysts say about Tandem Diabetes Care Inc. stockExplosive trading growth - Autocar Professional
Is Tandem Diabetes Care Inc. a good long term investmentUnprecedented market success - Autocar Professional
Tandem Diabetes Care Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Marriott Vacations, Wabash, SmartRent, Vestis, and Tandem Diabetes Stocks Trade Up, What You Need To Know - Yahoo Finance
Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More - Yahoo Finance
What drives Tandem Diabetes Care Inc. stock priceSuperior stock growth - jammulinksnews.com
Insulin Pump Market Booming with AI Integration, Attracts Focus - openPR.com
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) - Yahoo Finance
Wearable Injectors Market is expected to reach USD 24.99 billion - openPR.com
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Diabetes Devices Market is projected to grow to US$ 64.8 billion - openPR.com
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):